About
91±¬ΑΟ³ΙΘΛΖ¬ is a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system.
Our mission is to deliver a new class of treatments to improve the lives of people with 91±¬ΑΟ³ΙΘΛΖ¬, autoimmune disorders, and infectious diseases. β
Headquartered in Oxford, UK
Raised $131M from top venture capital funds
Founded in 2017 by Peter Joyce, former R&D Lead at Vertex Pharmaceuticals, and Tom McCarthy, former President and CEO of Spinifex Pharmaceuticals (acquired by Novartis for ~$700M).
We're looking for talented individuals to join our award-winning team. Do you have what it takes?
Our board
Dedicated professionals committed to advancing healthcare solutions.
Testimonials
"91±¬ΑΟ³ΙΘΛΖ¬ are doing incredible things and they are totally going to change the game - best thing since sliced bread."
Big Time Existing Investor
Partner, Acme Investment
Recent awards
2024 Best Established Biotech (Finalist)
Series B Raise of the Year
(Finalist)
(Finalist)
